Evidence map›Paper›PMID 23971054›Full record

ArticleJournal of diabetes research2013

IL-10 induction from implants delivering pancreatic islets and hyaluronan.

Paul L Bollyky, Robert B Vernon, Ben A Falk, Anton Preisinger, Michel D Gooden, Gerald T Nepom, John A Gebe

Open access · goldAbstract read
In one paragraph

Article in Journal of diabetes research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Inhibition of hyaluronan synthesis prevents β-cell loss in obesity-associated type 2 diabetes.Matrix biology : journal of the International Society for Matrix Biology · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Paul L BollykyDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Grant Building, 300 Pasteur Drive, Stanford, CA 94305-5107, USA.
Robert B Vernon
Ben A Falk
Anton Preisinger
Michel D Gooden
Gerald T Nepom
John A Gebe
Benaroya Research InstituteStanford University · US

Funding

Tissue Cytokine Sequestration and Immune Regulation in AutoimmunityU01AI101984 · NIAID · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$5.0M
Lymph Node Extracellular Matrix in Antigen Presentation and Immune RegulationR01DK096087 · NIDDK · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2021
$3.4M
ECM Costimulation of Immunoregulatory Pathways in Airway InflammationR01HL113294 · NHLBI · STANFORD UNIVERSITY · PI BOLLYKY, PAUL L · 2012 to 2016
$2.0M
NHLBI NIH HHS R01 HL113294NHLBI NIH HHS R01HL113294NIAID NIH HHS U01 AI101984NIAID NIH HHS U01AI101984NIDDK NIH HHS R01 DK096087
6 · The paper itself

Abstract

Local induction of pro-tolerogenic cytokines, such as IL-10, is an appealing strategy to help facilitate transplantation of islets and other tissues. Here, we describe a pair of implantable devices that capitalize on our recent finding that hyaluronan (HA) promotes IL-10 production by activated T cells. The first device is an injectable hydrogel made of crosslinked HA and heparan sulfate loaded with anti-CD3/anti-CD28 antibodies and IL-2. T cells embedded within this hydrogel prior to polymerization go on to produce IL-10 in vivo. The second device is a bioengineered implant consisting of a polyvinyl alcohol sponge scaffold, supportive collagen hydrogel, and alginate spheres mediating sustained release of HA in fluid form. Pancreatic islets that expressed ovalbumin (OVA) antigen were implanted within this device for 14 days into immunodeficient mice that received OVA-specific DO.11.10 T cells and a subsequent immunization with OVA peptide. Splenocytes harvested from these mice produced IL-10 upon re-challenge with OVA or anti-CD3 antibodies. Both of these devices represent model systems that will be used, in future studies, to further evaluate IL-10 induction by HA, with the objective of improving the survival and function of transplanted islets in the setting of autoimmune (type 1) diabetes.

Indexed as

AnimalsBioengineeringHyaluronic AcidHydrogelsInterleukin-10Islets of LangerhansIslets of Langerhans TransplantationLymphocyte ActivationMiceMice, TransgenicProstheses and ImplantsHyaluronic AcidHydrogelsInterleukin-10

Identifiers

PMID23971054
PMCPMC3736405
OpenAlexW2016569426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.